secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0000105770-22-000042
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q2 net sales $771M (+6.6%); cuts FY2022 guidance on FX and COVID decline
--------------------------------------------------------------------------------

- Q2 net sales $771.3M (+6.6% reported, +13.1% organic); reported EPS $2.48, adjusted EPS $2.47.
- Proprietary Products segment sales $653.7M (+11.3%, organic +18.3%) led by high-value components and devices.
- Contract-Manufactured Products sales $117.8M (-13.6%, organic -8.9%) on lower diagnostic device component sales.
- FY2022 guidance cut: net sales now $2.950-$2.975B (prior $3.050-$3.075B); adjusted EPS $9.00-$9.15 (prior $9.30-$9.45).
- Guidance reflects $190M FX headwind and ~$85M decline in COVID-19 sales; base business growth partially offsets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000042/0000105770-22-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000042/wst-20220728.htm
  HTML page:      https://secwatch.observer/filing/0000105770-22-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer